checkAd
    Day One Biopharmaceuticals Aktie
    17,690
     
    USD
    +0,68 %
    +0,120 USD
    Letzter Kurs 18:13:10 Nasdaq
    17,680
     
    USD
    200 STK
    Geldkurs 18:13:10
    17,710
     
    USD
    100 STK
    Briefkurs 18:13:10
    ISIN: US23954D1090 · WKN: A3CQ56 · SYM: DAWN · USA

    Neueste Nachrichten

    Day One’s OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
    23.04.24 · globenewswire · Day One Biopharmaceuticals
    Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
    26.02.24 · globenewswire · Day One Biopharmaceuticals
    Day One Announces Two New Appointments to Board of Directors
    17.01.24 · globenewswire · Day One Biopharmaceuticals
    Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    19.12.23 · globenewswire · Day One Biopharmaceuticals
    Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
    17.11.23 · globenewswire · Day One Biopharmaceuticals
    Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference
    14.11.23 · globenewswire · Day One Biopharmaceuticals
    Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
    06.11.23 · globenewswire · Day One Biopharmaceuticals
    Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
    30.10.23 · globenewswire · Day One Biopharmaceuticals
    Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
    12.09.23 · globenewswire · Day One Biopharmaceuticals
    Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
    11.09.23 · globenewswire · Day One Biopharmaceuticals
    Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
    16.08.23 · globenewswire · Day One Biopharmaceuticals
    Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
    07.08.23 · globenewswire · Day One Biopharmaceuticals